The 12th JFCR−ISCC
December 3-4, 2007
Keidanren Hall
December 3, 2007 (Monday)
12:00-13:00
(Committee Member Meeting)
Welcome and Introduction
13:30-13:40
Takashi Tsuruo (Cancer Chemotherapy Center, Tokyo)
I Kinase Inhibitors (Part I)
Chairpersons: Joseph Paul Eder (Dana Farber Cancer Inst., Boston)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)
13:40-14:20
Mark Ratain (Univ. of Chicago, Chicago)
Lessons learned from Sorafenib
14:20-14:45
Seiji Naito (Kyushu Univ., Fukuoka)
Sunitinib
14:45-15:25
Jaap Verweij (Erasmus Univ. Medical Center, Rotterdam)
Pazopanib, a novel multitargeted tyrosine kinase inhibitor: Safety and combinability with Lapatinib
15:25-15:35
Discussion
15:35-15:55
Coffee Break
II Kinase Inhibitors (Part II)
Chairpersons: Jaap Verweij (Erasmus Univ. Med. Center, Rotterdam)
Ryuzo Ueda (Nagoya City Univ., Nagoya)
15:55-16:35
Joseph Paul Eder (Dana Farber Cancer Inst., Boston)
The role combinations tyrosine kinase inhibition-more than one pathway, more than one agent?
16:35-17:00
Taira Maekawa (Kyoto Univ., Kyoto)
Bcr-Abl mutations and new agents in the treatment of imatinib-resistant Ph+ leukemias
17:00-17:25
Yoshikazu Sugimoto (Kyoritsu Univ. Pharm., Tokyo)
ABC transporters and signal transduction pathways
17:25-18:05
Elizabeth Eisenhauer (Queen's Univ., Ontario)
Review of phase II experience with targeted drugs:
predictors of success in phase III
18:05-18:15
Discussion
18:15-19:30
Mixer
December 4, 2007 (Tuesday)
III Nuclear Targets and DNA Damage
Chairpersons: Mark Ratain (Univ. of Chicago, Chicago)
Nagahiro Saijo (National Cancer Center Hospital East, Kashiwa)
09:30-09:55
Kimitoshi Kohno (Univ. Occup. Environment. Health, Fukuoka)
Cisplatin resistance and transcription factors
09:55-10:35
Yves G. Pommier (National Cancer Institute, Bethesda)
Topoisomerase inhibitors, camptothecins and beyond
10:35-10:50
Coffee Break
10:50-11:30
Edward A. Sausville (Univ. Maryland, Baltimore)
Aminoflavone: a novel damaging agent
11:30-12:10
Nicola Curtin (Univ. Newcastle upon Tyne, Newcastle)
PARP inhibitors for cancer therapy?
12:10-12:20
Discussion
12:30-13:30
Luncheon Seminars
Seminar I (Rm1001(10F))
presented by Taiho Pharmaceutical Co., Ltd.
Chairperson: Yuichi Ando (Nagoya Univ., Nagoya)
Mark Ratain (Univ. of Chicago, Chicago)
Pharmacogenetics of anticancer agents: Distinguishing scientific results from hypothesis
Seminar II (Rm1002(10F))
presented by Yakult Honsha, Co., Ltd.
Chairperson: Morito Monden (Osaka Univ., Osaka)
Axel Grothey (Mayo Clinic, Rochester)
The continuum of care in advanced colorectal cancer
IV TGF-β Signaling Inhibitors
Chairpersons: Edward A. Sausville (Univ. Maryland, Baltimore)
Yasuhiro Fujiwara (National Cancer Center Hospital, Tokyo)
13:55-14:40
Kohei Miyazono (Univ. Tokyo, Tokyo)
DDS of TGF-β inhibitor
14:40-14:50
Discussion
14:50-15:20
Coffee Break
VNew Targets & New Drugs (under Clinical Consideration)
Chairpersons: Yves G. Pommier (National Cancer Institute,
Bethesda)
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)
15:20-16:00
Axel Grothey (Mayo Clinic, Rochester)
Antiangiogenic therapy in cancer
16:00-16:40
James Christensen (Pfizer Global Research and Development, San Diego)
The role of c-Met in human cancer progression and the discovery and characterization of small molecule inhibitors for therapeutic intervention
16:40-17:05
Yuichi Hashimoto (Univ. Tokyo, Tokyo)
Biological response modifiers derived from thalidomide
17:05-17:15
Discussion
Closing Remark
17:15-17:25
Edward A. Sausville (Univ. Maryland, Baltimore)
